Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of “Buy” from Analysts

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has received a consensus recommendation of “Buy” from the fourteen brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, eleven have given a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $12.3846.

TSHA has been the topic of a number of recent research reports. Pivotal Research set a $14.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, June 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Wednesday. BMO Capital Markets boosted their target price on shares of Taysha Gene Therapies from $10.00 to $14.00 and gave the company an “outperform” rating in a research note on Tuesday, June 23rd. Citigroup restated an “outperform” rating on shares of Taysha Gene Therapies in a research note on Tuesday, June 23rd. Finally, Canaccord Genuity Group boosted their target price on shares of Taysha Gene Therapies from $14.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, April 6th.

Insider Activity at Taysha Gene Therapies

In other news, insider Sukumar Nagendran sold 200,000 shares of the business’s stock in a transaction on Friday, April 10th. The shares were sold at an average price of $4.46, for a total value of $892,000.00. Following the sale, the insider owned 1,136,410 shares in the company, valued at approximately $5,068,388.60. The trade was a 14.97% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 3.78% of the company’s stock.

Institutional Investors Weigh In On Taysha Gene Therapies

Institutional investors and hedge funds have recently made changes to their positions in the company. Marex Group plc acquired a new stake in shares of Taysha Gene Therapies in the 2nd quarter valued at $29,000. E Fund Management Co. Ltd. acquired a new stake in shares of Taysha Gene Therapies in the 2nd quarter valued at $31,000. Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new stake in shares of Taysha Gene Therapies in the 3rd quarter valued at $40,000. Tower Research Capital LLC TRC boosted its stake in shares of Taysha Gene Therapies by 156.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock valued at $41,000 after purchasing an additional 10,742 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its stake in shares of Taysha Gene Therapies by 143.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company’s stock valued at $43,000 after purchasing an additional 4,607 shares in the last quarter. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Price Performance

TSHA opened at $6.34 on Monday. Taysha Gene Therapies has a fifty-two week low of $2.25 and a fifty-two week high of $7.30. The company has a debt-to-equity ratio of 0.23, a current ratio of 14.04 and a quick ratio of 14.04. The firm’s fifty day moving average price is $6.11 and its two-hundred day moving average price is $5.29. The company has a market capitalization of $1.82 billion, a P/E ratio of -16.68 and a beta of 1.19.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). On average, analysts anticipate that Taysha Gene Therapies will post -0.5 EPS for the current year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.